Access to therapy for ulcerative colitis (UC) and Crohn disease (CD) may not be consistent with treatment guidelines because of payer policies that do not concur with the American Gastroenterological Association clinical pathways for the treatment of inflammatory bowel disease.
Biologics and other advanced therapies have revolutionized the treatment of a number of inflammatory diseases, with ulcerative colitis (UC) and Crohn disease (CD) in particular becoming subject to a more individualized treatment approach. However, access to therapy may not be consistent with treatment guidelines because of payer policies that do not concur with the American Gastroenterological Association clinical pathways for the treatment of inflammatory bowel disease.
In a paper recently published in Digestive Diseases and Sciences, a research team sought to identify whether insurance coverage for such therapies for UC and CD is routinely approved in clinical practice. In the study, they evaluated patient access to biologics and advanced small-molecule therapies using commercial and government policy information derived from the Managed Markets Insight and Technology database, as well as publicly available medical policies, prior authorization information, and pharmacy drug list documents.
In total, 301,748,186 and 302,057,543 lives were captured in the database under the medical and pharmacy benefits, respectively. The investigators assessed coverage for adalimumab, infliximab, biosimilar infliximab, the orally administered small-molecule drug tofacitinib, ustekinumab, and vedolizumab.
They found that 89% of lives required no or 1 prior biologic use before accessing any of the drugs of interest for the treatment of UC or CD, with the exception of tofacitinib in UC and subcutaneous ustekinumab for CD; access for these 2 therapies was 68% and 71%, respectively.
Products that had wider coverage were originator infliximab, biosimilar infliximab, and adalimumab. Originator and biosimilar infliximab were covered under the medical benefit without prior biologic failure for 95% of lives, and with the failure of 1 prior biologic for 89.8% for UC. The infliximab products were covered for 95% and 90% of lives, respectively, for CD.
Adalimumab was covered under the pharmacy benefit for 99% of lives, without prior biologic failure or with 1 prior biologic, for UC and CD.
Among newer drugs, vedolizumab had the widest coverage; for UC and CD, 81% of lives had access to the therapy without a prior biologic exposure. Tofacitinib had lower access, with 43% of lives having access without prior biologic exposure. Rates of coverage without a prior biologic for subcutaneous ustekinumab were lower (49%) than for the intravenously administered version of the drug (86%).
The authors write that approximately half of all covered lives had access to all biologics—although not to the small-molecule tofacitinib—as first-line therapy for UC and CD, and two-thirds had access after 1 biologic exposure.
“With the emergence of new therapies, including biosimilars, there will be an increased pressure on payers to manage therapies and an increased responsibility on physicians to choose the most appropriate agent,” conclude the authors, adding that “it is important that modern physicians understand how to navigate coverage policies and advocate to create an individualized treatment pathway for each patient.”
Reference
Dulai PS, Osterman MT, Lasch K, Cao C, Riaz F, Sandborn WJ. Market access analytics of biologics and small-molecule inhibitors for inflammatory bowel disease among US health insurance policies [published online March 28, 2019]. Dig Dis Sci. doi: 10.1007/s10620-019-05594-7.
The Growing Impact of Biosimilars in IBD Care
April 23rd 2025Biosimilars are proving to be a game-changing solution in the fight against inflammatory bowel disease (IBD), offering a cost-effective alternative to biologics with similar efficacy and safety, while innovative drug delivery systems promise to further enhance treatment outcomes and accessibility for millions worldwide.
Biosimilars Gastroenterology Roundup for November 2024—Podcast Edition
December 1st 2024On this episode of Not So Different, we discuss market changes in the adalimumab space; calls for PBM transparency and biosimilar access reforms grew; new data for biosimilars in gastroenterology conditions; and all the takeaways from this year's Global Biosimilars Week.
Biosimilar and Biologic Use Increasing in Greek Patients With IBD
April 19th 2025A retrospective study from a single inflammatory bowel disease (IBD) center in Greece reported that from 2018 to 2022, the use of biologics increased by 28% yearly, and the proportion of patients using biosimilars grew from 33% to 67%.
Biosimilars Gastroenterology Roundup for May 2024—Podcast Edition
June 2nd 2024On this episode of Not So Different, we review the biggest gastroenterology biosimilar stories from May 2024, covering new data from conferences and journals on infliximab and adalimumab products that demonstrate positive clinical results and confirm the safety of these biosimilars, as well as the feasibility of switching to them.
Early Success of Adalimumab Biosimilars Featured at AMCP 2025
April 5th 2025High adherence rates, comparable clinical effectiveness, and cost savings have marked the early adoption of adalimumab biosimilars in the US, particularly in formulary-driven transitions, as shown in 2 retrospective studies presented at the Academy of Managed Care Pharmacy annual meeting (AMCP 2025).
Biosimilars Gastroenterology Roundup: March 2025
April 1st 2025As the biosimilar industry celebrates a decade of growth, the market continues to evolve with expanded treatment options, cost savings, and a flurry of new competitors—yet regulatory challenges, market dynamics, and patient accessibility remain key hurdles to unlocking its full potential.